title: Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.
abstract: BACKGROUND
  The aim of the present study was to compare the reported efficacy and safety of glucagon-like peptide-l receptor agonist (GLP-1RA) and insulin glargine (IGlar) for poorly controlled type 2 diabetes.
  
  
  METHODS
  Medline, EMBASE, Cochrane Library, and clinicaltrials.gov were carried out. References and cited papers of relevant articles were also checked.
  
  
  RESULTS
  Seven trials met the inclusion criteria. GLP-1RA showed equivalent or superior efficacy to IGlar for reducing hemoglobin A1c (HbA1c), with a greater proportion of patients achieving HbAlc<7%. GLP-1RA also favored decreased body weight, total cholesterol (TC), low-density lipoprotein (LDL), and systolic blood pressure (SBP). Serious adverse events were uncommon and not significantly different. More patients taking GLP-1RA experienced gastrointestinal complications: nausea, diarrhea, and vomiting. Severe hypoglycemia events were rare, and minor hypoglycemia was less common for GLP-1RA.
  
  
  CONCLUSIONS
  GLP-1RA showed greater efficacy compared to IGlar for type 2 diabetes, and it may also prove beneficial for other diabetes-associated characteristics, including obesity, hypertension, and hyperlipidemia.
authors.affiliation: Department of Endocrinology, Central People's Hospital of Tengzhou City, Shandong, China.
authors.forename: Fu-peng
authors.initials: FP
authors.lastname: Liu
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Dong
authors.forename: Qing
authors.initials: Q
authors.lastname: Yang
authors.forename: Xian-zhong
authors.initials: XZ
authors.lastname: Xue
authors.forename: Zhong-fa
authors.initials: ZF
authors.lastname: Ren
authors.forename: Yi-zhang
authors.initials: YZ
authors.lastname: Gan
authors.forename: Lin
authors.initials: L
authors.lastname: Liao
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: GLP-1 receptor agonist; diabetes mellitus; hyperlipidemia; insulin glargine; 关键词：糖尿病，GLP-1受体激动剂，高血脂，甘精胰岛素